the aid library

LIST OPTIONS

Filter

1594

Selecting digital contact tracing and quarantine tools for COVID-19 : guiding principles and considerations for a stepwise approach

World Health Organization WHO, Western Pacific Region (2020) CC

Contact tracing is a key component of the COVID-19 response, particularly as societies begin to lift non-pharmaceutical interventions. However, it is a time-consuming and resource-intensive effort that depends on a trained and motivated workforce. Emergent digital contact tracing and quarantine (‎... more

Download (287)

View PDF (187)

Environmental and Social Management Framework (Final Report) for the COVID-19 Emergency Preparedness and Response Project

Ministry pf Health and Sanitation Sierra Leone (2021) CC

Download (119)

View PDF (145)

ACTUALIZACIÓN COVID-19

Ferres M., Potin M. (2020) C2

El presente material es un aporte NO OFICIAL y volutario realizado a partir de la reunión clínica del equipo de Infectología Pediátrica PUC. Su objetivo de aportar con un recurso educativo que contribuya a la actualización de los profesionales y estudiantes de la salud respecto a este problem... more

Download (254)

View PDF (283)

Mental Health in the times of COVID-19 Pandemic

National Institute of Mental Health & Neurosciences, Bengaluru India; Dept. of Psychiatry (2020) CC

Guidance for General Medical and Specialised Mental Health Care Settings

Download (192)

View PDF (196)

COVID-19: Guidelines for communicating about coronavirus disease 2019 - A guide for leaders

Pan American Health Organisation PAHO (2020) C_WHO

Risk communication encompasses all the basics of health communication but differs in the need for speed and reliance on trust. At times of crisis, leaders are called on to provide a quick, sensitive and trustworthy response.

Download (155)

View PDF (214)

Recomendaciones para el tratamiento hospitalario de la COVID-19 en pacientes adultos ( Version 10, 2020)

G, Zambrano, E Salgato, F. M. Moyano et al. (2020) CC

Recommendations for in-patient management of COVID-19 in adult patients Version 10, November 2020.

Download (335)

View PDF (446)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (154)

View PDF (157)

Interim Infection Prevention and Control Recommendations for Coronavirus Disease 2019 (COVID-19) in Health Care Settings

Ministry of Health, Kenya (2020) C2

Accessed: 02.05.2020 These interim IPC recommendations for health settings have been developed through the contributions of many individuals and institutions, such as the Centers for Disease Control-Kenya; ITECH; US Agency for International Development (USAID) Medicines, Technologies, and Pharmaceu... more

Download (256)

View PDF (271)

Lista de medicamentos esenciales para el manejo de pacientes que ingresan a unidades de cuidados intensivos con sospecha o diagnóstico confirmado de COVID 19. Tercera versión, 1 de febrero del 2022
recommended

Organización Mundial de la Salud OMS OPS (2022) C_WHO

List of essential medicines for the management of patients admitted in intensive care units with a suspected or confirmed diagnosis of COVID 19. Third version, 1 February 2022

Download (137)

View PDF (169)

Reprendre le travail en toute sécurité Guide sur la prévention du COVID-19 à l’intention des employeurs

International Labour Organisation (2020) CC

Ce guide a été préparé par le Bureau des activités pour les employeurs (ACT/EMP) de l’Organisation internationale du Travail et contient des recommandations sur les mesures pratiques et les méthodes à mettre en oeuvre en matière de santé et de sécurité pour la prévention du COVID-19.

Download (170)

View PDF (187)

COVID-19 Appeal: South Sudan Preparedness and Response Plan - July 2020 - June 2021

International Organization for Migration IOM (2020) C1

Download (131)

View PDF (172)

What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control?

Ryan, R.E.; et al. World Health Organization WHO, Regional Office of Europe (2021) C_WHO

Health Evidence Network synthesis report 72

Download (97)

View PDF (88)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

Download (116)

View PDF (148)

COVID-19 and Food Safety: Guidance for Food Businesses

World Health Organization WHO (2020) C_WHO

External Link

COVID-19 Vaccine Roll Outs in ASEAN & Asia – Live Updates by Country

Asean Briefing (2021) CC

It will be updated continuously. Details of COVID-19 availability in all ten ASEAN countries and another 30 Asian nations. Due to the developing situation in China and Asia concerning the Coronavirus, we will be operating this article as a running live update service to keep businesses involved in... more

Download (282)

View PDF (371)

Iraq: Coronavirus Disease 2021 (COVID-19) - Weekly Situation Report (Week 31) (2 – 8 Aug 2021)

Office for the Coordination of Humanitarian Affairs OCHA (2021) C2

Download (354)

View PDF (235)

Safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women

World Health Organization WHO (2021) C_WHO

COVID-19 Vaccines: 1 Safety Surveillance 2 Manual While there is no indication that pregnant women have an increased susceptibility to infection with SARS-CoV-2, there is evidence that pregnancy may increase the risk of severe illness and mortality from COVID-19 disease in comparison with non-pregn... more

External Link

Disability considerations for COVID-19 vaccination

World Health Organization WHO; UNICEF (2021) C_WHO

Available in Chinese, English, French, Russian and Spanish; WHO and UNICEF policy brief, 19 April 2021 Persons with disabilities are disproportionately impacted by COVID-19, both directly because of infection, and indirectly because of restrictions to reduce the spread of the virus. Persons with di... more

Download (146)

View PDF (199)

COVID-19 and the Displaced:Addressing the Threat of the Novel Coronavirus in Humanitarian Emergencies

Refugees International (2020) C1

Novel coronavirus will disproportionately impact world’s 70 million displaced people Report recommends stopping asylum seeker deportations, prioritising hygiene and refugee camp decongestion, better communication Displaced people must be included in prevention, mitigation efforts - for s... more

Download (134)

View PDF (205)

Manual Instrutivo para a assistência à gestante e puérpera frente à pandemia da covid-19

Ministerio da Saude, Brasilia (2020) CC

Instructional Manual for the care of pregnant and postpartum women in the context of the covid-19 pandemic Este Manual de Recomendações para a Assistência à Gestante e Puérpera visa orientar o acesso e a horizontalidade da assistência durante a pandemia Covid-19, abordando as vias de transmis... more

Lista de medicamentos esenciales para el manejo de pacientes que ingresan a unidades de cuidados intensivos con sospecha o diagnóstico confirmado de COVID 19. Tercera versión, 1 de febrero del 2022 recommended

Lista de medicamentos esenciales para el manejo de pacientes que ingresan a unidades de cuidados intensivos con sospecha o diagnóstico confirmado de COVID 19. Tercera versión, 1 de febrero del 2022
recommended